Wockhardt's new antibiotic, Miqnaf, has received a favourable recommendation from the Central Drugs Standard Control Organisation for treating community-acquired bacterial pneumonia in adults. The drug offers a convenient, once-a-day, three-day treatment. This could lead to final approval by the DCGI, benefiting patients with multi-drug resistant infections. Wockhardt shares rose by 5 percent.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.